| 33.91 -0.38 (-1.11%) | 04-19 12:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 47.91  |
1-year : | 53.99 |
| Resists | First : | 41.02 |
Second : | 46.22 |
| Pivot price | 37.1 |
|||
| Supports | First : | 32.61 |
Second : | 27.13 |
| MAs | MA(5) : | 34.43 |
MA(20) : | 38.24 |
| MA(100) : | 39.91 |
MA(250) : | 29.73 |
|
| MACD | MACD : | -2.6 |
Signal : | -2.3 |
| %K %D | K(14,3) : | 8.4 |
D(3) : | 6.5 |
| RSI | RSI(14): 28.8 |
|||
| 52-week | High : | 53.08 | Low : | 13.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARVN ] has closed above bottom band by 19.0%. Bollinger Bands are 14.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.92 - 34.13 | 34.13 - 34.32 |
| Low: | 32.32 - 32.56 | 32.56 - 32.79 |
| Close: | 33.08 - 33.44 | 33.44 - 33.77 |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Fri, 19 Apr 2024
Vontobel Holding Ltd. Takes $2.72 Million Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Thu, 18 Apr 2024
Multiple Insiders Sold Arvinas Shares Presenting Weak Signs For Investors - Simply Wall St
Tue, 16 Apr 2024
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update - MarketBeat
Thu, 11 Apr 2024
Arvinas, Novartis Partnering On Prostate Cancer Protein Degrader A Win-Win (NASDAQ:ARVN) - Seeking Alpha
Tue, 09 Apr 2024
Is Arvinas (ARVN) Stock a Solid Choice Right Now? - Yahoo Finance
Sun, 03 Mar 2024
Arvinas: Behind The Huge Rally (NASDAQ:ARVN) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 68 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 97.2 (%) |
| Shares Short | 8,600 (K) |
| Shares Short P.Month | 8,350 (K) |
| EPS | -6.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.71 |
| Profit Margin | 0 % |
| Operating Margin | 383.5 % |
| Return on Assets (ttm) | -19.5 % |
| Return on Equity (ttm) | -60 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.15 |
| EBITDA (p.s.) | -5.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -348 (M) |
| Levered Free Cash Flow | -198 (M) |
| PE Ratio | -5.18 |
| PEG Ratio | 0.2 |
| Price to Book value | 3.53 |
| Price to Sales | 29.73 |
| Price to Cash Flow | -6.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|